Clinical Trial

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-09-20; most recent amendment 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2022-09-27
Trial Details
NCT Number NCT04099966
Lead Sponsor Mitchell Cairo
Conditions Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Sickle Cell Disease +1 more
Enrollment 20 participants
Start Date 2021-04-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-08